io.github.builtforai/loe-exposure
loe-exposure
Drug patent expiries ranked by the Medicare Part D spending exposed to them
- 1.0.0
- Version
- remote
- Transport
- 1
- Tools
Security review
Review passedReviewed 1d ago.
- tools: 1 tools scanned
- metadata: scanned
No findings.
Tools (1)
loss_of_exclusivity_exposure
Rank upcoming FDA Orange Book patent and exclusivity expiries BY the gross Medicare Part D spending exposed to them, with marketed-generic status for each ranked drug resolved from live CMS NADAC price evidence. Answers which expiries matter, not merely which come first. Reports EXPOSURE, never forecast savings. Spending is gross of manufacturer rebates. Orange Book small molecules only, so biologics — among the largest Part D line items — are excluded, and the headline total must not be read as spending that will "go generic".